Literature DB >> 15837738

Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer.

Kazuhiko Ogawa1, Tohru Utsunomiya, Koshi Mimori, Fumiaki Tanaka, Hiroshi Inoue, Hisashi Nagahara, Sadayuki Murayama, Masaki Mori.   

Abstract

PURPOSE: Human kallikrein gene 6 (KLK6) is a member of the human kallikrein gene family, and recent studies have found that many kallikreins have altered expression patterns in various malignancies. The purpose of the current study was to quantify the expression of KLK6 in malignant and benign colorectal tissues and to statistically analyze whether KLK6 expression levels correlate with clinicopathologic variables and prognosis in patients with colorectal cancer. EXPERIMENTAL DESIGNS: Paired colorectal tissue samples from cancerous and corresponding noncancerous tissues were obtained from 63 patients with colorectal cancer who underwent surgical resection. Quantitative analyses of KLK6 mRNA expression were done using real-time quantitative reverse transcription-PCR.
RESULTS: KLK6 mRNA overexpression in cancerous tissues compared with normal counterparts was observed in 57 of 63 (90%) patients. The mean expression level of KLK6 mRNA in cancerous tissues was significantly higher than that in noncancerous tissues (P < 0.0001). Elevated KLK6 expression was significantly correlated with serosal invasion (P < 0.05), liver metastasis (P < 0.05), and advanced Duke's stage (P < 0.01). Furthermore, patients with high KLK6 expression had a significantly poorer actuarial overall survival than patients with low KLK6 expression (5-year overall survival rates: 54% and 73%, respectively, P < 0.05).
CONCLUSIONS: The results of this study indicated that KLK6 mRNA expression was significantly higher in cancerous than in noncancerous colorectal tissues, and high expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke's stage, and a poor prognosis for patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837738     DOI: 10.1158/1078-0432.CCR-04-2281

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

2.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

3.  Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells.

Authors:  Valérie Gratio; Céline Loriot; G Duke Virca; Katerina Oikonomopoulou; Francine Walker; Eleftherios P Diamandis; Morley D Hollenberg; Dalila Darmoul
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

4.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16

5.  Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Authors:  Rebecca S Henkhaus; Upal Kunal Basu Roy; Dora Cavallo-Medved; Bonnie F Sloane; Eugene W Gerner; Natalia A Ignatenko
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

6.  Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Authors:  Rebecca S Henkhaus; Eugene W Gerner; Natalia A Ignatenko
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

7.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

8.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.

Authors:  M Talieri; L Li; Y Zheng; D K Alexopoulou; A Soosaipillai; A Scorilas; D Xynopoulos; E P Diamandis
Journal:  Br J Cancer       Date:  2009-04-14       Impact factor: 7.640

9.  Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis.

Authors:  M Iwatsuki; T Fukagawa; K Mimori; H Nakanishi; S Ito; H Ishii; T Yokobori; M Sasako; H Baba; M Mori
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

10.  KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.

Authors:  N M A White; M Mathews; G M Yousef; A Prizada; C Popadiuk; J J E Doré
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.